Joseph (“Joe”) Amprey, M.D., Ph.D. Senior Managing Director, MedImmune Ventures, Inc.
Joe joined MedImmune in 2006 as a principal within MedImmune Ventures to assist in deal sourcing and portfolio management and became a Managing Director in 2007. He comes to MedImmune Ventures from Carrot Capital (CCHV) where he was responsible for deal sourcing and had operational roles within CCHV’s portfolio companies. Previously, Joe completed an internship in internal medicine at both New York–Presbyterian Hospital and Memorial Sloan-Kettering Cancer Center. During medical school, Joe was an independent consultant to Arch Venture Partners. He earned a bachelor’s degree in biochemistry from the University of Pennsylvania, and received both a doctorate in immunology and a medical degree from Cornell University’s Weill Medical College. Joe sits on the board of Synovex, Inc and is an observer on the boards of Ambit Biosciences, Inc, Elusys Therapeutics, Inc, and VLST, Inc.
Franklin (“Frank”) H. Top, Jr., M.D. Senior Vice President, MedImmune Ventures, Inc.
As senior vice president of MedImmune Ventures, Inc., Frank identifies companies that may be suitable for partnership and investment opportunities. He also serves as medical counsel to the clinical development group at MedImmune, Inc. Frank joined MedImmune in June 1988 as executive vice president and was elected to the board of directors where he served from 1988 to 2003. He became the company’s medical director in 1990, and held that position until he was appointed senior vice president of MedImmune Ventures in July 2004. Prior to joining MedImmune, Frank served as senior vice president for clinical and regulatory affairs at Praxis Biologics from 1987 to 1988. Prior to 1987, he served for 22 years in the U.S. Army Medical Research and Development Command, where he was appointed Director and Commandant, Walter Reed Army Institute of Research, in 1983. Frank holds a doctorate of medicine cum laude and a bachelor of science degree in biochemistry from Yale University. Frank is a board member of VaxInnate, Inc., Applied Genetic Technologies Corporation and GlycoMimetics, Inc. and previously Avidia, Inc.
Eva M. Jack Managing Director, MedImmune Ventures, Inc.
Eva recently joined MedImmune Ventures from MedImmune Business Development. She joined the company in 2004 and was in charge of initiating in-licensing and research collaborations with universities, medical research institutions and governments. In addition, she was responsible for some out-licensing of intellectual property portfolio to companies and other interested third parties. Prior to joining MedImmune in 2004, Eva held a variety of positions at Intel Corporation during her 13 years with the company. In her last position at Intel, she worked for Intel Capital, the company’s venture fund, and was responsible for investments and research collaborations in biotechnology and health care. Eva began her career with Intel in Washington, DC as a lobbyist covering health care, immigration, labor law, and education and training issues. Eva holds a bachelor’s degree from the University of Virginia and a master’s degree in health sciences from The Johns Hopkins University. Eva is a board observer of Ligocyte, Inc.
Maggie Flanagan LeFlore, Ph.D. Managing Director, MedImmune Ventures, Inc.
Maggie, who joined MedImmune Ventures as a managing director in 2007, transitioned into the role from her position as Head of R&D Ventures at AstraZeneca. As Head of R&D Ventures, she was on assignment to Advent International where she worked with the Healthcare and Life Sciences venture capital investment team. Previously, Maggie was the Global Alliance Director for Global Sciences and Information from 2001 to 2005, where she led an international group responsible for evaluation, negotiation and management of global technology platform collaborations. Prior to 2001, Maggie held business development and scientific management positions at Hybridon, Inc. (1997-2000); Oncogene Science Inc. (1994-1996); and Merrell Dow Pharmaceuticals (1985-1994). Originally trained as a biophysical chemist, with a B.S. in Chemistry from the University of Kansas, and a Ph.D. in Physical Chemistry from Indiana University, she trained in molecular and cellular biology as a post-doctoral fellow at the National Institutes of Health. Maggie is a board observer of Inotek, Inc, and Brain Cells, Inc.